Hepion pharmaceuticals' rencofilstat, in combination with an immune checkpoint inhibitor, demonstrates synergistic anti-tumor activity in a nonclinical liver cancer study

Anti-tumor activity observed in fatty livers suggests rencofilstat may increase the treatment potential of anti-pd1 treatment in human liver cancer anti-tumor activity observed in fatty livers suggests rencofilstat may increase the treatment potential of anti-pd1 treatment in human liver cancer
HEPA Ratings Summary
HEPA Quant Ranking